<DOC>
	<DOCNO>NCT00465933</DOCNO>
	<brief_summary>The purpose study evaluate efficacy all-trans retinoic acid ( ATRA ) idarubicin ( AIDA ) dose reduction patient older 70 year age remission induction acute promyelocytic leukemia ( APL ) . With regard induction , excellent result obtain combination ATRA idarubicin ( AIDA ) , especially term antileukemic efficacy ( 1 % resistance ) , support introduction substantial change combination . However , give induction failure cause complication , especially hemorrhagic nature , major impact hyperleukocytic form patient older 70 year age , induction modify follow : 1 . Reduction idarubicin dose patient older 70 year age ( three day instead four ) ; 2 . Early administration corticosteroid therapy patient ATRA syndrome prophylaxis . A preliminary analysis Italian Group Adult Hematologic Diseases ( Gruppo Italiano Malattie Ematologiche dell'Adulto , GIMEMA ) show low dose prednisone use prophylactic manner appear reduce incidence severity ATRA syndrome , could also favorable impact hemorrhagic mortality ( non-published data ) ; 3 . Treatment hyperfibrinolysis antifibrinolytic agent ( tranexamic acid ) . It recently report APL cell present abnormally high level annexins ( especially annexin II ) , level may provide fundamental mechanism hemorrhagic complication APL increase production t-PA dependent plasmin . These finding provide new reason introduction tranexamic acid hemorrhagic prophylaxis APL .</brief_summary>
	<brief_title>Treatment Acute Promyelocytic Leukemia With All-Trans Retinoic Acid ( ATRA ) Idarubicin ( AIDA )</brief_title>
	<detailed_description>Induction chemotherapy : All-trans retinoic acid , administer mouth ( PO ) first day dose 45 mg/m²/day , fractionate 2 dos . In patient age &lt; 20 year , ATRA dose reduced 25 mg/m²/day fractionate 2 dos . The treatment ATRA continue CR achieve maximum 90 day case persistence atypical promyelocytes bone marrow . Idarubicin , 12 mg/m² day 2 , 4 , 6 8 treatment slow intravenous infusion ( 20 minute ) . In patient older 70 year age 3 dos idarubicin give day 2 , 4 , 6 . Supporting measure : Prednisone , 0.5 mg/kg/day day 1 15 . Tranexamic acid , 100 mg/kg/day continuous perfusion , platelet &lt; 50 x 10^9/L evident clinical-biological sign coagulopathy . This treatment discontinue platelet count &gt; 50 x 10^9/L . Transfusion platelet concentrate keep count 30 x 10^9/L first 10 day PRC maintain hemoglobin level great 9 g/dL . Prophylactic heparin use .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Age &lt; = 75 year ECOG = 3 . Morphological diagnosis M3 M3v . Those case without typical morphology PMLRARa rearrangement may also include . Genetic diagnosis : ( 15 ; 17 ) , PMLRARa rearrangement , monoclonal antiPML positive . Obviously , result test may become available initiated treatment base tentative morphological diagnosis . The presence secondary cytogenetic change associate ( 15 ; 17 ) reason exclusion require different therapeutic approach . Age &gt; 75 year ( treatment protocol consider individual basis patient analyse separately ) Absence PMLRARa rearrangement . Prior antileukemic chemotherapy . Presence associate neoplasm . Presence severe psychiatric disease . HIV seropositivity . Contraindication intensive chemotherapy , especially anthracyclines . Serum creatinine = 2.5 mg/dL . Bilirubin , alkaline phosphatase , SGOT &gt; 3 time upper normal limit Positive pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Acute Promyelocytic Leukemia</keyword>
	<keyword>AIDA</keyword>
</DOC>